Dyadic Q2 revenue up 150% to $967K; net loss narrows; completes $5.3M equity offering

DYADIC INTERNATIONAL INC

2025-Q2 EPS reported -$0.13 vs consensus -$0.06 ▼ miss (-112.4%)

Q2 2025 revenue $967K vs $386K YoY; net loss $1.794M ($0.06/share) vs $2.045M ($0.07).
Cash $7.3M at June 30; $5.3M net from August 1 equity offering (6.052M shares at $0.95).
Rebranded as Dyadic Applied BioSolutions; targeting 2025 commercial launch of animal-free serum albumin with Proliant.
Received $1.5M second installment from Gates Foundation mAb grant; expects $500K Proliant milestone in Q3 2025.
Inzymes milestone $250K received; EN3ZYME enzyme cocktail launched with Fermbox Bio under revenue share.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.